<DOC>
	<DOCNO>NCT01595789</DOCNO>
	<brief_summary>The purpose study investigate effect combine glucagon-like-peptide-1 ( GLP-1 ) analogue metformin therapy glucose metabolic cardiovascular endpoint compare metformin monotherapy patient coronary artery disease ( CAD ) newly diagnose type 2 diabetes ( T2D ) . It hypothesize GLP-1 analogue add backbone therapy metformin CAD patient T2D improve beta-cell function , leave ventricular ejection fraction ( LVEF ) , heart rate variability lower 24h blood pressure among select endpoint . The present study CAD patient newly diagnose T2D address select endpoint investigator initiate , randomize , double blind , crossover , placebo-controlled 12 + 12 week intervention study 2 week wash-out period .</brief_summary>
	<brief_title>The Effect Liraglutide Treatment Coronary Artery Disease Type 2 Diabetes</brief_title>
	<detailed_description>The total study period patient 26 week ( 12 plus 12 week intervention 2 week wash-out period ) . The endpoint evaluate baseline ( week 0 ) , week 12 , week 14 ( follow 2 week wash-out ) finally week 26 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Stable CAD document one following : Previous MI ( minimum 6 week acute MI ) Previous coronary revascularization CAD confirm abnormal coronary angiography ( CAG ) CTangiography show stenosis &gt; 50 % major coronary artery . 2 . Body mass index ( BMI ) &gt; /= 25,0 kg/m2 3 . Age &gt; /= 18 year &lt; /= 85 year 4 . Type 2 diabetes diagnose one follow criterion : HbA1c &gt; /= 6.5 % HbA1c &lt; 6.5 % fast plasma glucose &gt; /= 7.0 mmol/l ( confirm ) HbA1c &lt; 6.5 % 2 h plasma glucose value OGTT &gt; /= 11.1 mmol/l The data glucose metabolism accept provide obtain within 24 month prior inclusion patient . The glucose metabolic category define ADA WHO criteria . Type 1 diabetes mellitus define Cpeptide &lt; 450 pM Previously diagnose diabetes mellitus 24 month prior screen procedure trial , except gestational diabetes Use 2 type oral antidiabetic medication and/or use parenteral antidiabetic medication period 3 month prior screen visit . It accept patient continue usual antidiabetic medication screen visit antidiabetic medication must discontinue 2 week prior baseline visit . Significant heart disease ( NYHA &gt; 2 ; Ejection Fraction &lt; 40 % unstable angina pectoris ) know severe valve disease Documented atrial fibrillation atrial flutter within 6 week previous screen . Paroxysmal atrial fibrillation accept sinus rhythm achieve screening . Uncontrolled arterial hypertension ( &gt; 180/100 mmHg ) time screen Liver ( transaminase great x 2 upper normal level ) renal disease ( eGFR &lt; 60 ml/min ) Amylase great x 3 upper reference value Any chronic medical condition unduly increase risk potential enrollee judge study investigator Dysregulated myxedema hyperthyroid condition define value TSH &lt; 0,1 &gt; 10,0 milli U/L Anemia ( &lt; 85 % low normal limit ) , leucopenia ( &lt; 85 % low normal limit ) , thrombocytopenia ( &lt; 85 % low normal limit ) Pregnancy failure comply contraception plan within two year , breastfeed Abuse alcohol drug , coexist condition would make patient unsuitable participate study , judge investigator Use immunosuppressive therapy precede 12 month Chronic pancreatitis previous acute pancreatitis Known suspect hypersensitivity trial product ( ) relate product Treatment oral glucocorticoid , calcineurin inhibitor , dipeptidyl peptidase 4 ( DPP4 ) inhibitor , GLP1 mimetics ( e.g . exenatide ) , Investigator 's opinion could interfere glucose metabolism Cancer ( except basal cell skin cancer squamous cell skin cancer ) clinically significant disorder , Investigator 's opinion could interfere result trail Inflammatory bowel disease Previous bowel resection Clinical sign diabetic gastroparesis Plasma calciumion &gt; /= 1,45 mmol/L Plasma calcitonin &gt; /= 50 ng/L Subjects personal family history medullary thyroid carcinoma personal history multiple endocrine neoplasia type 2 Refusal sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Left ventricular ejection fraction</keyword>
	<keyword>Beta-cell function</keyword>
</DOC>